diphenyl ethylphosphonate | 7526-29-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diphenyl ethylphosphonate
• 英文别名: ethyl-phosphonic acid diphenyl ester；Aethyl-phosphonsaeure-diphenylester；Aethylphosphonsaeure-diphenylester；Aethylphosphorsaeure-diphenylester；Ethanphosphonsaeurediphenylester；Diphenyl-ethylphosphonat；Phosphonic acid, ethyl-, diphenyl ester；[ethyl(phenoxy)phosphoryl]oxybenzene
• CAS: 7526-29-6
• 化学式: C₁₄H₁₅O₃P
• 分子量: 262.245
• InChiKey: UHMQAIKRVPHZGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  diphenyl ethylphosphonate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以39%的产率得到ethylphosphonofluoridic acid
  参考文献：
  名称：

  Direct ¹⁸F-Labeling of Biomolecules via Spontaneous Site-Specific Nucleophilic Substitution by F^– on Phosphonate Prostheses

  摘要：

  DOI：

  10.1021/acs.orglett.1c01211
• 作为产物：
  描述：

  diphenyl ethylphosphonite 在 四氯化碳 、 苯甲醛 作用下， 生成 diphenyl ethylphosphonate
  参考文献：
  名称：

  Kharrasova,F.M. et al., Journal of general chemistry of the USSR, 1978, vol. 48, p. 948 - 952

  摘要：

  DOI：

文献信息

• Phosphorus-containing hepatitis C serine protease inhibitors
  申请人：Moore Joel D.

  公开号：US20080039375A1

  公开（公告）日：2008-02-14

  The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或式II的磷衍生化合物，或其药用可接受的盐、酯或前药，这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的主体进行管理。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• Reaction of P-N Compounds with Alkylating Reagents such as Alkyl Benzenesulfonates and Dialkyl Sulfates
  作者：Jugo Koketsu、Yoshio Ishii

  DOI：10.1246/bcsj.43.2527

  日期：1970.8

  The reaction of N,N′-dialkyl-diphenylphosphinous amides (I) with alkyl benzenesulfonates (III) or dialkyl sulfates (IV) took place exothermally, giving phosphonium salts (V). When phosphonium salts (V) were heated at 100°C for 5–10 hr, asymmetric phosphine oxide (VI) and N,N′-dialkyl-benzenesulfonamides (VII) or polymeric materials were obtained. In the case of diphenyl dialkylphosphoramidites (II)

  N,N'-二烷基-二苯基次膦酰胺(I)与烷基苯磺酸盐(III)或二烷基硫酸盐(IV)的反应放热发生，得到鏻盐(V)。当鏻盐 (V) 在 100°C 下加热 5-10 小时时，会得到不对称氧化膦 (VI) 和 N,N'-二烷基苯磺酰胺 (VII) 或聚合物材料。在二苯基二烷基亚磷酰胺 (II) 的情况下，在室温下未观察到季铵化。然而，当加热混合物时，通过中间体鏻盐获得二苯基烷基膦酸酯(VIII)和N,N'-二烷基苯磺酰胺(VII)或相同的聚合物材料。
• Butyrylcholinesterase Inhibitors
  申请人：JAL Therapeutics, LLC

  公开号：US20160206635A1

  公开（公告）日：2016-07-21

  Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.

  丁酰胆碱酯酶抑制剂，它们的配方，以及它们主要用于治疗神经退行性疾病。这些抑制剂通常是磷酸酯、膦酸酯、膦酸酯和磷酰胺酯。这些抑制剂可以被纳入药物组成，并以治疗有效量的方式给患者使用，以治疗神经退行性疾病。
• BUTYRYLCHOLINESTERASE INHIBITORS
  申请人：Acey Roger A.

  公开号：US20100069337A1

  公开（公告）日：2010-03-18

  Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.

  丁酰胆碱酯酶抑制剂，它们的配方，主要用于治疗神经退行性疾病。这些抑制剂通常是磷酸酯、膦酸酯、膦酸酯和磷酰胺酯。这些抑制剂可以被纳入药物组合物中，并以治疗有效剂量的形式给患者使用，以治疗神经退行性疾病。
• OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
  申请人：Hanson Gunnar J.

  公开号：US20120065169A1

  公开（公告）日：2012-03-15

  Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位连接和/或修改的3'和/或5'-末端基团的寡核苷酸类似物。所披露的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病非常有用。